Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Fresenius Kabi Huari Pharmaceutical is a leading healthcare company in China focused on clinical nutrition and infusion therapy. Established in 1982 as the first pharmaceutical joint venture in the country, it was originally known as Sino-Swed Pharmaceutical Corp. Ltd. The company is now a core subsidiary of the German-based Fresenius Kabi, specializing in products for patients who are critically ill or suffer from chronic conditions. Its extensive product portfolio includes parenteral nutrition, enteral nutrition, and a variety of intravenous generic drugs and infusion technologies. The company operates a large-scale, state-of-the-art manufacturing facility in Wuxi, Jiangsu Province, which serves as a hub for its Asian operations. Through its commitment to high-quality standards and innovation in medical nutrition, the company plays a pivotal role in the Chinese hospital market.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Fresenius Kabihuarui Pharmaceutical.